PURPOSE: The aim of this study was to investigate the independent significance of prognostic factors in stage I invasive epithelial ovarian cancer (EOC). PATIENTS AND METHODS: Between 1980 and 1994, all patients with stage I EOC (borderline tumors excluded) following surgical resection were entered onto this study. No patient received adjuvant therapy and patients were monitored as follows: years 1 to 2-physical examination and serum CA125 every 3 months and computed tomographic (CT) scan every 6 months; years 3 to 5-physical examination and serum CA125 every 6 months and CT scan yearly; years 5 to 10-annual physical examination and serum CA125, with CT scan if clinically indicated. RESULTS: A total of 194 patients entered the study. The median patient age was 54 years (range, 15 to 83), and the median follow-up duration 54 months (range, 7 to 157). Five-year survival rates were as follows: stage IA, 93.7%; stage IB, 92%; and stage IC, 84%. Multivariate analysis using Cox's regression identified grade (P < .001), presence of ascites (P = .05), and surface tumor (P < .01) as independent poor prognostic factors. International Federation of Gynecology and Obstetrics (FIGO) substage did not appear to have independent prognostic significance. Intraoperative capsule rupture was not found to be prognostically significant. The impact of pre-operative rupture remains unclear. CONCLUSION: This is an important series, as no patient received adjuvant therapy, and represents the natural history of surgically resected stage I EOC.
PURPOSE: The aim of this study was to investigate the independent significance of prognostic factors in stage I invasive epithelial ovarian cancer (EOC). PATIENTS AND METHODS: Between 1980 and 1994, all patients with stage I EOC (borderline tumors excluded) following surgical resection were entered onto this study. No patient received adjuvant therapy and patients were monitored as follows: years 1 to 2-physical examination and serum CA125 every 3 months and computed tomographic (CT) scan every 6 months; years 3 to 5-physical examination and serum CA125 every 6 months and CT scan yearly; years 5 to 10-annual physical examination and serum CA125, with CT scan if clinically indicated. RESULTS: A total of 194 patients entered the study. The median patient age was 54 years (range, 15 to 83), and the median follow-up duration 54 months (range, 7 to 157). Five-year survival rates were as follows: stage IA, 93.7%; stage IB, 92%; and stage IC, 84%. Multivariate analysis using Cox's regression identified grade (P < .001), presence of ascites (P = .05), and surface tumor (P < .01) as independent poor prognostic factors. International Federation of Gynecology and Obstetrics (FIGO) substage did not appear to have independent prognostic significance. Intraoperative capsule rupture was not found to be prognostically significant. The impact of pre-operative rupture remains unclear. CONCLUSION: This is an important series, as no patient received adjuvant therapy, and represents the natural history of surgically resected stage I EOC.
Authors: Emily N Prendergast; Marie Holzapfel; Jennifer J Mueller; Mario M Leitao; Camille C Gunderson; Kathleen N Moore; Britt K Erickson; Charles A Leath; Elena S Diaz Moore; Joshua G Cohen; Christine S Walsh Journal: Gynecol Oncol Date: 2016-12-12 Impact factor: 5.482
Authors: M M AlHilli; S C Dowdy; A L Weaver; J L St Sauver; G L Keeney; A Mariani; K C Podratz; J N Bakkum-Gamez Journal: Gynecol Oncol Date: 2011-12-28 Impact factor: 5.482
Authors: Peter G Rose; James J Java; Ritu Salani; Melissa A Geller; Angeles Alvarez Secord; Krishnansu S Tewari; David P Bender; David G Mutch; Michael L Friedlander; Linda Van Le; Michael W Method; Chad A Hamilton; Roger B Lee; Robert M Wenham; Saketh R Guntupalli; Maurie Markman; Franco M Muggia; Deborah K Armstrong; Michael A Bookman; Robert A Burger; Larry J Copeland Journal: Obstet Gynecol Date: 2019-02 Impact factor: 7.661
Authors: José A García-Sáenz; Ana Custodio; Antonio Casado; José Antonio Vidart; Pluvio J Coronado; Miguel Martín; Sara López-Tarruella; Javier Puente; Cristina Fernández; Eduardo Díaz-Rubio Journal: Clin Transl Oncol Date: 2011-02 Impact factor: 3.405
Authors: Aparna A Kamat; Mavis Fletcher; Lynn M Gruman; Peter Mueller; Adriana Lopez; Charles N Landen; Liz Han; David M Gershenson; Anil K Sood Journal: Clin Cancer Res Date: 2006-03-15 Impact factor: 12.531